Cervical cancer is the fourth most commonly occurring malignancy in females worldwide. Accumulated studies have demonstrated that the aberrant expression of microRNAs plays important roles in tumorigenesis and tumor development and potentially serves as therapeutic targets in various cancers including cervical cancer. Therefore, the identification of specific microRNAs contributed to cervical cancer formation and progression would provide critical clues for the treatments for patients with this disease. In this study, we aimed to detect microRNA-337 expression pattern and investigate the biological roles of microRNA-337 in the regulation of the malignant phenotypes of cervical cancer and its underlying mechanisms. We found that microRNA-337 expression was significantly downregulated in cervical cancer tissues and cell lines. In addition, its aberrant expression levels were positively correlated with tumor size, International Federation of Gynecology and Obstetrics stage, and lymph node metastasis of cervical cancer. The ectopic expression of microRNA-337 suppressed cell proliferation and invasion of cervical cancer in vitro. Furthermore, specificity protein 1 was identified as a direct target of microRNA-337 in cervical cancer. The expression of specificity protein 1 increased in cervical cancer tissues and negatively correlated with microRNA-337 expression level. Moreover, rescue experiments revealed that upregulation of specificity protein 1 could rescue the effects of microRNA-337 on cervical cancer cells. Taken together, these findings collectively demonstrate that microRNA-337 exerts its tumor-suppressing roles in cervical cancer by directly targeting specificity protein 1, thereby indicating a potential novel potential therapeutic target for patients with cervical cancer.
Introduction
Cervical cancer is the fourth most commonly occurring malignancy in women worldwide, and nearly 87% occur in developing parts of the world. 1 Approximately 528,000 new cases and 266,000 deaths are due to cervical cancer every year. 2 Cervical cancer is a complex disease that involves the transformation of the normal cervical epithelium into a preneoplastic cervical intraepithelial neoplasia that is subsequently transformed into invasive cervical cancer. 3 Currently, the standard strategies for patients with cervical cancer are surgery resection, radiotherapy, and chemotherapy. 4 Despite much effort in the treatments of cervical cancer, the overall survival rate of patients with cervical cancer remains unsatisfactory with a 5-year survival rate of less than 40%. 5, 6 Tumor invasion and metastasis are responsible for approximately 90% of all cancer-related deaths. 7 Thus, further exploration of the molecular mechanisms underlying the cervical cancer initiation and progression and investigating the effective therapeutic strategies for cervical cancer patients is necessary.
Much attention has been focused recently on the roles of microRNAs (miRNAs) in the carcinogenesis and progression of human cancers. 8, 9 MiRNAs are a novel group of endogenous, non-coding, and short RNA molecules ranging in size from 18 to 25 nucleotides. 10 MiRNAs regulate the expression of their target genes at the post-transcriptional and/or translational level by binding to the 3′-untranslated regions (3′-UTRs) of their target genes, resulting in degradation of target gene messenger RNAs (mRNAs) or inhibition of protein translation. 11, 12 To date, more than 1000 miRNAs have been predicted in the human genome and that can modulate thousands of human protein-coding genes. 12 Through this mechanism of post-transcriptional gene regulation, miRNAs are extensively involved in multiple diverse biological processes, including cell growth, differentiation, morphogenesis, cell cycle, apoptosis, migration, and invasion. 13 The abnormal expression of miRNAs has been reported in various human cancers. [14] [15] [16] MiRNAs can function as tumor suppressors or oncogenes in different human cancers mainly depending on their target genes. 17 Several miRNAs have been reported to play important roles in cervical cancer initiation and progression. Zhao et al. 18 found that the expression levels of miR-20a and miR-203 were significantly higher in cervical cancer patients and closely related to lymph node metastasis (LNM). Ribeiro et al. 19 observed that the expression of miR-125b could be significantly changed within the different cervical lesions which suggested that miR-125b might be involved in cervical cancer development. Shi and Zhang detected that miR-362 was downregulated in both cervical cancer tissues and cell lines. The upregulation of miR-362 could reduce cell proliferation, migration, and invasion of cervical cancer by negative regulation of SIX1. 20 In addition, previous study also reported that overexpression of miR-138, 21 miR-139-3p, 22 miR-375, 23 and miR-146a 24 inhibited cell proliferation, migration, and invasion and induced cell apoptosis in cervical cancer cells. Therefore, regulation of cancer-related miRNAs may provide therapeutic targets in human cancer treatments.
Previously, we analyzed the expression profiles of miRNA in multiple cancers using a publicly available database (Database of Differentially Expressed miRNAs in Human Cancers (version 2.0, dbDEMC 2.0, http:// www.picb.ac.cn/dbDEMC/)) and found that miR-337 was abnormally expressed in various cancers, such as lymphoma, 25 breast cancer, 26 hepatocellular carcinoma, 27 colon cancer, 28 lung cancer, 29 pancreatic cancer, 30 and ovarian cancer. 31 However, the role of miR-337 in cervical cancer has not been completely elucidated. In this study, we profiled the expression level of miR-337 in cervical cancer tissues and cell lines. Moreover, we investigated the biological roles of miR-337 in the regulation of the malignant phenotypes of cervical cancer and its underlying mechanisms.
Material and methods

Tissue samples and cell lines
A total of 49 pairs of human cervical cancer tissues and adjacent non-tumorous tissues were collected from Yantai Yuhuangding Hospital who underwent cervical biopsy. Based on the grading of cancer, the patients were further classified by pathological analysis into different grades according to the grading system of the International Federation of Gynecology and Obstetrics (FIGO). All tissues were snap-frozen immediately after surgery and stored at −80°C freezer.
Four cervical cancer cell lines (HeLa, Ca-Ski, C-33A, and SiHa), and HEK293T cells were obtained from Cell Bank of Type Culture Collection of the Chinese Academy of Sciences (Shanghai, China) and cultured in Dulbecco's Modified Eagle's Medium (DMEM; Gibco, Grand Island, NY, USA) containing 10% fetal bovine serum (FBS; Gibco), 100 IU/mL penicillin, and 100 µg/mL streptomycin (Gibco). A human normal cervical epithelial cell line (Ect1/E6E7) was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA) and cultured in keratinocyte serum-free medium containing 0.1 ng/mL human recombinant epithelial growth factor, 0.05 mg/mL bovine pituitary extract, 100 IU/mL penicillin, and 100 µg/mL streptomycin (all from Gibco). All cells were maintained at 37°C in a humidified incubator with 5% CO 2 .
RNA extraction and reverse transcription quantitative polymerase chain reaction
Total RNA was extracted from tissues or cells using TRIzol® reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's instructions. Reverse transcription quantitative polymerase chain reaction (RT-qPCR) was performed with an Applied Biosystems® 7900HT RT-PCR system (Thermo Fisher Scientific, Waltham, MA, USA). To quantify miR-337 expression, complementary DNA (cDNA) was synthesized using TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA), followed by qPCR with TaqMan MicroRNA PCR Kit (Applied Biosystems). For Sp1 mRNA expression, total RNA was subjected to first-strand cDNA synthesis using a PrimeScript RT Reagent kit (Takara, Osaka, Japan). The qPCR was then carried out using SYBR Pre-mix ExTaq (Takara). The U6 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were employed as endogenous control for miR-337 and Sp1 mRNA expression, respectively. The primers used in this study were as follows: miR-337:
Cell transfection
The miR-337 mimics and negative control miRNA mimics (miR-NC) were obtained from Shanghai GenePharma Co. Ltd. (Shanghai, China). Sp1-overexpressed vector (pCDNA3.1-Sp1) and corresponding empty vector (pCDNA3.1) were obtained from Chinese Academy of Sciences (Changchun, China). For transient transfection, cells were seeded into six-well plates and transfected at a density of 60%-70% confluence. Cell transfection was performed with Lipofectamine 2000 reagent (Invitrogen) in accordance with the manufacturer's instruction. About 24 h after transfection, cells were harvested and subjected to gene expression analysis and functional assays.
Cell Counting Kit 8 assay
Cell viability was determined using Cell Counting Kit 8 (CCK8) assay (BioSharp, Beijing, China). Transfected cells were harvested and seeded in 96-well plates at a density of 3000 cells per well. Cells were incubated in a humidified incubator at 37°C and 5% CO 2 for 24-96 h. CCK8 assay was performed every 24 h. Briefly, 10 µL of CCK8 solution was added to each well and incubated at 37°C for additional 4 h. Finally, the absorbance at a wavelength of 450 nm was detected using an automatic multiwell spectrophotometer (Bio-Rad, Richmond, CA, USA).
Cell invasion assay
Transfected cells were harvested, washed twice with FBSfree DMEM medium, and then re-suspended in FBS-free DMEM medium. A total of 1 × 10 5 cells were added into the upper chamber of transwell culture plates (8 µm pore size; Corning-Costar, Corning, NY, USA) coated with Matrigel (BD Bioscience, San Jose, CA, USA). About 600 µL DMEM containing 20% FBS was added into the lower chamber of the transwell culture plates. After 48 h incubation in a humidified incubator at 37°C and 5% CO2, cells remaining on the upper surface of the membranes were carefully removed with cotton swabs. Cells that had penetrated through to the lower surface of the membranes were fixed with 4% paraformaldehyde, stained with 0.5% crystal violet, washed with phosphate-buffered saline (PBS), and dried in air. The invaded cells were counted under a light microscope (×200 magnification; Olympus Corporation, Tokyo, Japan).
MiR-337 targets prediction
The target genes of miR-337 were analyzed using the following TargetScan (http://www.targetscan.org/index.html) and miRanda (http://www.microrna.org).
Luciferase reporter assay
For luciferase reporter assay, luciferase plasmid pGL3-Sp1-3′-UTR wild-type (Wt) and pGL3-Sp1-3′-UTR mutant (Mut) were synthesized and confirmed by GenePharma. HEK293T cells were seeded in 24-well plates at a density of 40%-50% confluence. Cells were transfected with pGL3-Sp1-3′-UTR Wt or pGL3-Sp1-3′-UTR Mut, and together with miR-337 mimics or miR-NC using Lipofectamine 2000, following the manufacturer's instructions. Luciferase activities were determined at 48 h post-transfection using Dual-Luciferase Reporter Assay System (Promega Corporation, Madison, WI, USA). Renilla activities were measured as an internal control.
Protein extraction and western blot
Radioimmunoprecipitation assay (RIPA) buffer (Beyotime Institute of Biotechnology, Jiangsu, Haimen, China) was used to isolate total protein from transfected cells according to the manufacturer's instruction. The concentration of total protein was measured using the BCA Protein Assay Kit (Thermo Fisher Scientific, Inc., Rockford, IL, USA). Equal amounts of protein were separated by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel and moved to the polyvinyl fluoride (PVDF) membranes (Millipore, Bedford, MA, USA). Then, the membranes were completely dipped into 5% nonfat milk in Tris-buffered saline with Tween 20 (TBST) for 2 h at room temperature followed by incubation with primary antibodies overnight at 4°C. The membranes were further developed with goat anti-mouse horseradish peroxidase (HRP)-conjugated secondary antibody (1:5000 dilution, sc-2005; Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 2 h at room temperature. At last, enhanced chemiluminescence system (Pierce Biotechnology, Inc., Rockford, IL, USA) was utilized to visualize protein bands. The primary antibodies used in this study were mouse anti-human monoclonal Sp1 antibody (1:1000 dilution, sc-17824; Santa Cruz Biotechnology) and mouse anti-human monoclonal GAPDH antibody (1:1000 dilution, sc-137179; Santa Cruz Biotechnology). GAPDH was used as an internal control.
Statistical analysis
Experiments were repeated at least three times and data were expressed as mean ± standard deviation (SD). The difference between groups was compared with two-tailed Student's t test or analysis of variance (ANOVA) using SPSS 19.0 statistical software (SPSS Inc, Chicago, IL, USA).
Student-Newman-Keuls (SNK) was used to compare between two groups in multiple groups study. Differences were considered significant at p < 0.05.
Results
MiR-337 was downregulated in cervical cancer tissues and cell lines
We first measured miR-337 expression in 49 pairs of human cervical cancer tissues and adjacent non-tumorous tissues via quantitative RT-qPCR. The expression level of miR-337 was lower in cervical cancer tissues compared with that in adjacent non-tumorous tissues, as shown in Figure 1 (a) (p < 0.05). We then investigate the association between miR-337 and clinicopathological features in cervical cancer. The median miR-337 expression level (median = 0.87) was set as the cutoff to divide all cervical cancer patients into either miR-337 low-expression group (n = 25) or the miR-337 high-expression group (n = 24). As shown in Table 1 , low-expression level of miR-337 was significantly correlated with tumor size (p = 0.003), FIGO stage (p = 0.015), and LNM (p = 0.013). However, there were no significant correlations between miR-337 expression and age (p = 0.644) or family history of cancer (p = 0.656).
RT-qPCR was then utilized to determine the miR-337 expression in four cervical cancer cell lines (HeLa, Ca-Ski, C-33A, and SiHa) and a human normal cervical epithelial cell line (Ect1/E6E7). The results indicated that miR-337 was lowly expressed in cervical cancer cell lines compared to Ect1/E6E7 (Figure 1(b) ; p < 0.05). The results suggested that the downregulation of miR-337 might play an important role in cervical cancer development.
MiR-337 overexpression suppressed cell proliferation and invasion of cervical cancer
First, HeLa and Ca-Ski cells were transfected with miR-337 mimics or miR-NC. RT-qPCR was used to assess the transfection efficiency (Figure 2 assay. Ectopic expression of miR-337 suppressed the proliferation of HeLa and Ca-Ski cells, as shown in Figure 2 (c) and (d). We also observed that miR-337 overexpression significantly reduced the invasion capacity of HeLa and Ca-Ski cells (Figure 2 (e) and (f); p < 0.05). These results suggested that miR-337 significantly inhibited cervical cancer tumorigenesis and tumor development.
Sp1 is a direct target of miR-337 in cervical cancer
Bioinformatics analysis identified that Sp1 may be a putative target of miR-337 and the 3′-UTR of Sp1 contains two highly conserved binding sites from position 1468 to 1474 and 3366 to 3373 for miR-337 seed sequence (Figure 3(a) ). Among these candidate targets, Sp1 was significantly upregulated in cervical cancer and was involved in cervical cancer formation and progression. 32, 33 Luciferase reporter assays were then used to explore whether the 3′-UTR of Sp1 can be directly targeted by miR-337. The results showed that upregulation of miR-337 reduced the luciferase activities of pGL3-Sp1-3′-UTR Wt (Figure 3 
MiR-337 is inversely correlated with Sp1 expression in cervical cancer
We further detected Sp1 expression in cervical cancer tissues to evaluate its association with miR-337 expression. First, RT-qPCR was performed to determine Sp1 mRNA expression in cervical cancer tissues and adjacent nontumorous tissues. We found that Sp1 mRNA and protein was obviously increased in cervical cancer tissues compared with adjacent non-tumorous tissues (Figure 4 (a) and (b); p < 0.05). Spearman's correlation analysis showed a significant negative correlation between Sp1 mRNA and miR-337 expression in cervical cancer tissues (r = −0.6144, p < 0.0001; Figure 4(c) ). 
Restoration expression of Sp1 partially reverses the inhibitory effects of miR-337 on cervical cancer cells
In order to determine whether Sp1 mediated the suppressing roles of miR-337 in cervical cancer, rescue experiments were performed in HeLa and Ca-Ski cells. Western blot analysis confirmed that Sp1 was upregulated in HeLa and Ca-Ski cells transfected with pcDNA3.1-Sp1 ( Figure  5(a) ; p < 0.05). Subsequently, CCK8 assay and cell invasion assay revealed that overexpression of Sp1 partially rescued miR-337-mediated suppression of the proliferation ( Figure 5 
Discussion
Accumulated studies demonstrated that the aberrant expression of miRNAs plays important roles in tumorigenesis and tumor development and potentially serves as therapeutic targets in various cancers including cervical cancer. 20, 34, 35 Therefore, the identification of specific miRNAs contributed to cervical cancer formation, and progression would provide critical clues for the treatments for patients with this disease. In this study, miR-337 was significantly downregulated in both cervical cancer tissues and cell lines. Low-expression level of miR-337 was correlated with tumor size, FIGO stage, and LNM of cervical cancer patients. Functional assays revealed that the restoration expression of miR-337 repressed the cell proliferation and invasion of cervical cancer. More importantly, Sp1 was validated as a direct target of miR-337 in cervical cancer. Collectively, our data indicated that miR-337 might be associated with the progression of cervical cancer malignancy. Previous studies demonstrated that miR-337 played important roles in the tumorigenesis and tumor development. For example, miR-337 was underexpressed in tumor samples and tissues in non-small-cell lung cancer. The enforced expression of miR-337 improved the chemosensitivity of non-small-cell lung cancer cell to paclitaxel and docetaxel by directly targeting STAT3 and RAP1A. 36 In colorectal cancer, miR-337-enhanced cellular senescence through negative regulation of α subunit of protein kinase CKII. 37 In gastric cancer, miR-337 expression was lower and significantly correlated with LNM. Upregulation of miR-337 inhibited the cell growth, invasion, metastasis, and angiogenesis in gastric cancer in vitro and in vivo through downregulating myeloid zinc finger 1-facilitated expression of matrix metalloproteinase 14. 38 In pancreatic ductal adenocarcinoma, miR-337 was downregulated in tumor tissues and strongly associated with TNM (tumor, node, and metastasis) stage and lymph node status. In addition, the expression level of miR-337 was correlated with longer survival. 39 Moreover, miR-337 targeted HOXB7 to suppress cell proliferation and invasion in vitro. 40 In neuroblastoma, miR-337 expression level was decreased in tumor tissues. In vitro and in vivo experiment assays indicated that miR-337 overexpression obviously attenuated cell growth, invasion, metastasis, and angiogenesis. 41 These researches suggested that miR-337 plays important roles in multiple types of human cancer and may therefore be a therapeutic target in their treatment.
Having characterized the tumor-suppressing roles of miR-337 in cervical cancer, we next attempted to identify the potential targets of miR-337. Bioinformatics analysis predicted that Sp1 was a target of miR-337. In this study, Sp1 was demonstrated to be a novel target of miR-337. In addition, a luciferase reporter assay indicated that miR-337 binds directly to the 3′-UTR of the Sp1 mRNA. To examine the regulatory effects of miR-337 on endogenous Sp1 expression, RT-qPCR and western blot analyses were utilized to measure Sp1 expression at the mRNA and protein levels in cervical cancer cells following transfection with miR-337 mimics or miR-NC. Results revealed that Sp1 was significantly reduced at both mRNA and protein level in miR-337 mimics-transfected cervical cancer cells. Furthermore, Sp1 was upregulated in cervical cancer tissues and inversely correlated with miR-337 expression level. Moreover, the upregulation of Sp1 could rescue the effects of miR-337 on cervical cancer cells, thus further verifying that Sp1 is a direct and functional target gene of miR-337 in cervical cancer.
Sp1 is a member of the specificity protein/Krüppel-like factor (Sp/KLF) transcription factor family and is expressed ubiquitously in many tissues, as well as interacts with the GC-rich (5′-GGGGCGGGG-3′) motif in promoters. 42, 43 Sp1 expression is upregulated in numerous types of cancer, such as prostate cancer, 44, 45 breast cancer, 46 pancreatic cancer, 42 lung cancer, 47 and gastric cancer. 48 Sp1 is related to growth, differentiation, migration, metastasis, and invasion of multiple tumors. 42, 49, 50 Previous studies indicate that the expression of Sp1 is increased in cervical cancer tissues. 32 Moreover, Sp1 is involved in cervical cancer cell proliferation, apoptosis, radiosensitivity, and metastasis. 23, 33, [51] [52] [53] Our results suggested that miR-337 inhibited cell proliferation and invasion through reducing the Sp1 expression. Thereby, both miR-337 and Sp1 might be developed as therapeutic targets for the suppression of human cervical cancer. miR-337 overexpression or Sp1 underexpression could attenuate cell malignant behaviors and consequently block the progression of cervical cancer.
In conclusion, this study demonstrated that miR-337 acted as a tumor growth and metastasis suppressor in cervical cancer, at least partially through downregulation of Sp1. This finding suggested that miR-337 may represent a novel effective therapeutic target for cervical cancer treatments in future.
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